journal
https://read.qxmd.com/read/38631301/a-hematoma-in-the-anterior-abdominal-muscle-in-a-woman-receiving-venlafaxine-a-literature-review-of-the-reports-on-similar-cases
#1
Chrysoula Boutari, Evangelia Zarkada, Athanasios Vyzantiadis, Efthymia Vlachaki, Genovefa Mantzou, Cristine Karipidou, Stamatia Theodoridou
INTRODUCTION: Venlafaxine (VEN) is a selective norepinephrine reuptake inhibitor (SNRI) that mainly helps treat major depressive disorder and anxiety and panic disorders. It works by inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NA) by presynaptic neurons. Additionally, VEN administration has been linked with a bleeding predisposition, that may be due to the inhibition of NA and 5-HT uptake by platelets which have their own receptors on their surface and are implicated in platelet aggregation...
April 17, 2024: Acta Haematologica
https://read.qxmd.com/read/38626745/prognostic-implications-of-circulating-plasma-cell-percentage-in-multiple-myeloma-and-primary-plasma-cell-leukemia-defined-by-new-criteria
#2
JOURNAL ARTICLE
Xianghong Jin, Xianyong Jiang, Hui Li, Kaini Shen, Shuangjiao Liu, Miao Chen, Chen Yang, Bing Han, Junling Zhuang
INTRODUCTION: The definition of primary plasma cell leukemia (pPCL) has been revised from ≥20% to ≥5% circulating plasma cells (CPC). However, the precise prognosis associated with CPC remains controversial. This study aimed to investigate prognostic biomarkers for myeloma patients based on CPC presence. METHODS: A comprehensive analysis was conducted on 309 consecutive patients diagnosed with either multiple myeloma or pPCL, utilizing peripheral blood smears stained with Wright-Giemsa...
April 16, 2024: Acta Haematologica
https://read.qxmd.com/read/38615657/efficacy-safety-and-quality-of-life-of-pegcetacoplan-in-japanese-patients-with-paroxysmal-nocturnal-hemoglobinuria-treated-within-the-phase-3-pegasus-trial
#3
JOURNAL ARTICLE
Hisakazu Nishimori, Hideyuki Nakazawa, Shinobu Tamura, Toshiki Uchida, Kensuke Usuki, Johan Szamosi, Régis Peffault de Latour, Alexander Röth, Jens Panse
INTRODUCTION: Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inadequate response to eculizumab. METHODS: This analysis evaluates the efficacy and safety of pegcetacoplan for Japanese patients in PEGASUS, as they are known for different clinicopathologic features compared to non-Asian patients...
April 12, 2024: Acta Haematologica
https://read.qxmd.com/read/38599195/long-term-efficacy-and-safety-of-damoctocog-alfa-pegol-prophylaxis-in-patients-with-haemophilia-a-aged-12-18-years-at-enrolment-into-protect-viii
#4
JOURNAL ARTICLE
Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso
Introduction The phase 2/3 PROTECT VIII study demonstrated long-term efficacy and safety of damoctocog alfa pegol (BAY 94-9027; Jivi®), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to improve its pharmacokinetic profile. Aim We report a post hoc assessment of bleeding and safety outcomes in the subgroup of patients, aged 12-<18 years at enrolment. Method PROTECT VIII was a multicentre, open-label study of previously treated males aged 12-65 years with severe haemophilia A (FVIII<1%)...
April 10, 2024: Acta Haematologica
https://read.qxmd.com/read/38574468/failure-of-treatment-free-remission-after-a-prolonged-deep-molecular-response-in-patients-with-chronic-myeloid-leukemia
#5
Patrice E Nasnas, Elias J Jabbour, Koji Sasaki, Ghayas C Issa, Lucia Masarova, Nicholas J Short, Fadi G Haddad
Patients with chronic myeloid leukemia in chronic phase (CML-CP) can have a normal life expectancy when treated with the BCR::ABL1 tyrosine kinase inhibitors. In recent years, treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with CML-CP. Deep and sustained molecular remissions for more than 3 to 5 years are associated with higher chances of a successful TFR. However, although uncommon, some patients may still experience molecular or hematological relapse after treatment discontinuation, even after a prolonged duration of remission...
April 4, 2024: Acta Haematologica
https://read.qxmd.com/read/38565097/consensus-based-expert-recommendations-on-the-management-of-hemophilia-a-in-the-gulf-region
#6
REVIEW
Hazzaa Abdulla Alzahrani, Ashraf Warsi, Ali Mullah-Ali, Ghazi Alotaibi, Mahmoud Abu-Riash, Mohammad Alshahrani, Mustaqeem Siddiqui, Tarek Owaidah, Shahrukh Hashmi
BACKGROUND: Hemophilia A presents a significant health challenge in the Gulf region, where it has an especially high prevalence. There are several unmet needs associated with the management of hemophilia A in the region. The aim of this manuscript is to contextualize unmet management needs, provide recommendations to optimize care, and specify requirements for the establishment of gene therapy centers in the region. SUMMARY: An expert panel was assembled comprising ten clinical hematologists from Kuwait, Oman, Saudi Arabia, and the United Arab Emirates...
April 2, 2024: Acta Haematologica
https://read.qxmd.com/read/38527433/utility-of-echocardiogram-in-neutropenic-patients-with-gram-positive-bacteremia-a-retrospective-study
#7
Neta Sternbach, Haim Ben-Zvi, Ofir Wolach, Moshe Yeshurun, Pia Raanani, Dafna Yahav, Liat Shargian
INTRODUCTION: Hemato-oncology patients are vulnerable to bloodstream infections due to immunocompromised state and use of intravascular catheters. Data regarding risk of infective endocarditis (IE) among those with gram positive bacteremia is limited. We aimed to evaluate the incidence of IE among neutropenic hemato-oncology patients, and to explore the yield of echocardiogram in this population. METHODS: we conducted a single retrospective study of all hospitalized hemato-oncology neutropenic patients with gram positive blood cultures between 2007 and 2021...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38527425/the-ratio-of-serum-urea-nitrogen-to-albumin-is-a-better-predictor-of-os-in-mm-patients-than-urea-nitrogen-alone
#8
JOURNAL ARTICLE
Jiaqi Shao, Enfan Zhang, Haoguang Chen, Zhen Cai, Mengmeng Dong
Introduction Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Abnormally cloned plasma cells secrete large amounts of monoclonal immunoglobulins in the bone marrow of MM patients. Serum urea nitrogen (sUN) is a byproduct of protein metabolism, and its effect on MM patients' prognoses remains unknown. Therefore, we analysed MM patients' clinical data to explore the role of sUN and serum urea nitrogen/serum albumin (sUAR) in the baseline tumor load and MM prognosis of MM patients. Methods We downloaded the clinical data of 762 MM patients from the MMRF database...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38527424/long-non-coding-rna-rp11-252c15-1-is-a-potential-biomarker-of-prognosis-and-hallmark-for-leukemogenesis-in-children-with-b-cell-precursor-acute-lymphoblastic-leukemia
#9
JOURNAL ARTICLE
Lili Pan, Yongzhi Zheng, Hao Zheng
INTRODUCTION: Improved understanding of the prognostic biomarkers associated with childhood acute lymphoblastic leukemia (ALL) is needed for accurate risk group stratification. This study aimed to identify potential long-non coding RNA (lncRNA) markers and evaluate their prognostic value in children with ALL. METHODS: We selected 50 children with newly diagnosed ALL and 20 age-matched patients with idiopathic immune thrombocytopenia (controls). RNA sequencing was performed to identify differentially expressed lncRNAs between the ALL and control groups...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38479365/the-ire1%C3%AE-endonuclease-plays-a-dual-role-in-regulating-the-xbp1-mirna-34a-axis-and-pd-1-expression-within-natural-killer-cells-in-hodgkin-lymphoma
#10
JOURNAL ARTICLE
Karolina Bednarska, Gayathri Thillaiyampalam, Sally Mujaj, Jamie Nourse, Jay Gunawardana, Muhammed B Sabdia, Soi C Law, Anna Pilaar, Qingyan Cui, Lilia M de Long, Frank Vari, Maher K Gandhi, Alexandre S Cristino
INTRODUCTION: Hodgkin Lymphoma (HL) is deficient in Major Histocompatibility Complex-class I, rendering it susceptible to anti-tumoral immunity by Natural Killer (NK)-cells. Despite the functional impairment of PD-1+ NK-cells in HL, the underlying mechanisms of NK-cell dysfunction remain unclear. METHODS: This study involved 14 HL patients and SNK10/KHYG-1 cell lines to assess NK-cell activation against cancer cells. Activation was measured through transcript (PCR) and protein expression (flow cytometry)...
March 13, 2024: Acta Haematologica
https://read.qxmd.com/read/38471491/efficacy-of-preexposure-prophylaxis-with-monoclonal-antibody-tixagevimab-cilgavimab-against-emerging-sars-cov-2-resistant-variants-in-patients-with-chronic-lymphocytic-leukemia
#11
JOURNAL ARTICLE
Ohad Benjamini, Tamar Tadmor, Abraham Avigdor, Rotem Gershon, Limor Kliker, Florin Fares, Nofar Atari, Ilana Laevsky, Bayan Abd Elkader, Tammy Hod, Orit Golan-Shany, Michal Mandelboim, Galia Rahav
Introduction Pre exposure prophylaxis with monoclonal antibodies (mAbs) were developed in addition to COVID19 vaccine for immunocompromised and those with insufficient immune response, among them patients with CLL. Omicron variant and its sublineages evolved mutations that escape mAbs neutralizing effect, yet the extent of which was not studied. Methods We evaluated anti-spike titters and neutralization activity of COVID-19 wild type (WT) , Delta , Omicron, BA2, BA4 and BA5 before and after tixagevimab-cilgavimab (TGM/CGM) dose of 150/150mg or 300/300mg in patients with CLL...
March 12, 2024: Acta Haematologica
https://read.qxmd.com/read/38461815/the-effect-of-mind-body-intervention-on-lymphocyte-doubling-time-and-treatment-free-survival-in-treatment-na%C3%A3-ve-chronic-lymphocytic-leukemia-patients
#12
JOURNAL ARTICLE
Shirley Shapira, Naama Hirschberger, Yishai Ofran, Barak Mizrahi, Esti Mandel, Ohad Benjamini, Noa Rabinowicz, Adi Zoref-Lorenz
INTRODUCTION: Mind-Body Intervention (MBI) serves as supportive aid in oncology. We hypothesized that MBI could impact the progression of Chronic Lymphocytic Leukemia (CLL) in the 'watch and wait' (w&w) phase. METHODS: MBI was utilized in a non-randomized prospective controlled study between 02/2020-02/2022 in 76 treatment-naïve CLL patients in the w&w phase (37 intervention and 39 control patients). The primary and secondary endpoints were prolongation of Lymphocyte Doubling Time (LDT) and treatment-free survival (TFS)...
March 8, 2024: Acta Haematologica
https://read.qxmd.com/read/38447541/peeling-back-the-layers-recurrent-talquetamab-skin-toxicity-after-supportive-stem-cell-boost-in-multiple-myeloma
#13
Alexander D Heini, Vera Ulrike Bacher, Dilara Akhoundova, Katja Seipel, Thomas Pabst
Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a supportive hematopoietic stem cell boost to treat persistent late cytopenias after CAR-T therapy...
March 6, 2024: Acta Haematologica
https://read.qxmd.com/read/38432198/primary-nodal-epstein-barr-virus-positive-t-cell-nk-cell-lymphoma-real-world-experience
#14
JOURNAL ARTICLE
Dae-Ho Choi, Sang Eun Yoon, Junhun Cho, Seok Jin Kim, Won Seog Kim
PTCL-EBV is a disease entity newly recognized in the WHO-HAEMS5 and the ICC of Mature Lymphoid neoplasms classification. Previously, it was classified as a subtype within PTCL-NOS and was known to have a poor prognosis. However, the clinical feature and treatment outcomes are not well known. This retrospective observational study was conducted on patients diagnosed with PTCL-EBV at Samsung Medical Center through a pathology review from 2000 to 2020. We analyzed clinical data from 14 patients. We conducted an investigation of patients with PTCL-EBV into immunohistochemistry and analysis of survival outcomes for each treatment regimen...
March 3, 2024: Acta Haematologica
https://read.qxmd.com/read/38432204/venous-thromboembolism-prophylaxis-in-inflammatory-bowel-disease-inpatients-systematic-review-and-meta-analysis
#15
Rotem McNeil, Danielle Fredman, Ofir Eldar, Anat Gafter-Gvili, Tomer Avni
INTRODUCTION: Inflammatory bowel disease (IBD) patients are three-times more likely to develop venous thromboembolism (VTE), and guidelines recommend prophylaxis during all hospitalizations. In this systematic review we sought to assess for the benefits and risks of VTE prophylaxis in hospitalized IBD patients. METHODS: We performed a systematic review and meta-analysis. We searched MEDLINE and others up to 2/2022, for studies on IBD inpatients treated with prophylactic anti-coagulation during hospitalization, compared to no prophylaxis...
March 1, 2024: Acta Haematologica
https://read.qxmd.com/read/38432202/impacts-of-posttransplant-cyclophosphamide-dose-on-graft-versus-leukemia-effects-via-hla-b-leader-in-hla-haploidentical-peripheral-blood-stem-cell-transplantation
#16
Makoto Moriguchi, Kentaro Ido, Hiroshi Okamura, Mika Nakamae, Kazuki Sakatoku, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Asao Hirose, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
INTRODUCTION: The graft-versus-leukemia effect of HLA-B leader dimorphism, i.e. methionine (M) or threonine (T) at position -21 of the leader sequence, has been observed in HLA-haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (PTCy-haplo). However, the biological mechanism has been unclear, and the contributions of HLA-B leader genotype to risk reduction of relapse might be dependent on posttransplant cyclophosphamide (PTCy) doses. METHODS: To investigate whether the effect of HLA-B leader dimorphism was modified by the PTCy dose, we retrospectively analyzed 99 patients who received PTCy-haplo...
March 1, 2024: Acta Haematologica
https://read.qxmd.com/read/38417413/impact-of-covid-19-on-patients-with-beta-thalassemia-major-an-observational-study
#17
JOURNAL ARTICLE
Nadia Vacca, Cristian Locci, Fabiola Serra, Elena Chicconi, Mariangela V Puci, Giovanni Sotgiu, Antonio Matteo Amadu, Roberto Antonucci
INTRODUCTION:  The prevalence of COVID-19 is slightly lower, and its mortality is higher in beta-thalassemia patients than in the general population. We evaluated the impact of COVID-19 in terms of incidence, clinical course, management, and specific antibody response to vaccination in a cohort of patients with beta-thalassemia major. METHODS:  We retrospectively enrolled all transfusion-dependent beta-thalassemia major patients attending the Thalassemia Day Care Center of the University Hospital of Sassari, Italy, from March 1, 2020, to May 31, 2021...
February 28, 2024: Acta Haematologica
https://read.qxmd.com/read/38412838/erratum
#18
(no author information available yet)
No abstract text is available yet for this article.
February 27, 2024: Acta Haematologica
https://read.qxmd.com/read/38408440/zanubrutinib-plus-cytarabine-in-patients-with-refractory-relapsed-primary-central-nervous-system-lymphoma
#19
JOURNAL ARTICLE
Zhiguang Lin, Jingjing Ma, Yan Ma, Qing Li, Hui Kang, Mengxue Zhang, Bobin Chen
INTRODUCTION: Primary central nervous system lymphoma (PCNSL) is a rare subtype of aggressive extranodal non-Hodgkin lymphoma. Currently, there is no standard of care for the treatment of refractory or relapsed PCNSL (r/r PCNSL). We conducted a prospective single-arm phase II study to evaluate zanubrutinib plus cytarabine for r/r PCNSL. METHODS: Using Simon's two-stage design, we analyzed 34 patients who received high-dose cytarabine (3.0 g/m2 once daily) for 2 days and zanubrutinib (160 mg twice daily) for 21 days each cycle for up to 6 cycles...
February 26, 2024: Acta Haematologica
https://read.qxmd.com/read/38402867/oncogenic-mtor-signaling-axis-compensates-btk-inhibition-in-a-chronic-lymphocytic-leukemia-patient-with-richter-transformation-a-case-report-and-review-of-the-literature
#20
Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar, Daniel Neureiter, Lisa Pleyer, Alexander Egle, Richard Greil, Roland Geisberger, Nadja Zaborsky
INTRODUCTION: Targeting the B cell receptor (BCR) pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates...
February 24, 2024: Acta Haematologica
journal
journal
21868
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.